Dexpanthenol injections under the skin for chronic wounds such as diabetic foot ulcers
Tests dexpanthenol injections added to standard care in adults with chronic wounds.
Key facts
- Who runs it
- Dilara CANBAY OZDEMIR
- Where
- Türkiye1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Subcutaneous Dexpanthenol Administration and Wound Epithelialization
- Status
- Not yet recruiting
- People taking part
- 40 people, planned
- Starts
- 2 Dec 2026
- Expected to end
- 2 Dec 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Dexpanthenol
- Standard Wound Care
- Record updated
- 22 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a chronic wound that is not infected, such as a diabetic foot ulcer, venous leg ulcer or arterial ulcer. Some will get dexpanthenol injections under the skin around the wound, plus standard wound care.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- A chronic wound between 1 and 20 cm² in size, with no infection. No pus, bad smell, spreading redness or signs of infection in the body. Patients must be clinically stable.
- Earlier treatment
- People must not need antibiotic treatment taken by mouth or into the blood.
Main reasons for not taking part
- Wound infection or need for antibiotics through the body
- Severe lack of blood flow to the leg (ankle-brachial index <0.5, pain at rest, gangrene or large areas of dead tissue)
- Wound showing bone, tendon or joint, or suspected bone infection
- Wound caused by cancer, autoimmune disease, blood vessel inflammation or certain skin diseases
- Pregnancy or breastfeeding, or allergy to dexpanthenol
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Adults aged 18 years and older
- Presence of a chronic wound, including diabetic foot ulcer, venous leg ulcer, or arterial ulcer
- Target wound size between 1 and 20 cm² at baseline
- Non-infected wound, defined by the absence of purulent discharge, foul odor, spreading erythema, cellulitis, or systemic signs of infection
- Clinically stable patients without the need for systemic antibiotic therapy
- Ability to understand the study procedures and provide written informed consent
- Willingness and ability to comply with study visits and treatment schedule
Who cannot take part
- Clinical signs of wound infection or requirement for systemic antibiotic treatment
- Malignant, autoimmune, vasculitic, or specific dermatologic conditions causing the wound
- Known hypersensitivity or allergy to dexpanthenol or any component of the study treatments
- Cognitive impairment or inability to provide informed consent
- Any medical condition that, in the investigator's judgment, could compromise participant safety or study integrity
- Critical limb ischemia, defined as ankle-brachial index <0.5, rest pain, gangrene, or extensive tissue necrosis
- Wounds exposing bone, tendon, or joint structures, or suspected osteomyelitis
- Wound size smaller than 1 cm² or larger than 20 cm²
- Pregnancy or breastfeeding
- Participation in another interventional clinical trial that could interfere with the outcomes of this study
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Chronic wounds are wounds that do not heal properly over time and can significantly reduce quality of life. Common types include diabetic foot ulcers, venous leg ulcers, and arterial ulcers. Improving wound healing and speeding up skin regeneration (epithelialization) are important goals in the care of these patients.
Read full original descriptionShow less
Dexpanthenol is a vitamin B5 derivative that supports skin repair and tissue regeneration. It is widely used in topical treatments, and injectable forms are approved for clinical use. However, the effects of subcutaneous (under the skin) dexpanthenol injections on chronic wound healing have not been sufficiently studied in clinical settings.
The purpose of this study is to evaluate whether adding subcutaneous dexpanthenol injections to standard wound care improves wound healing compared with standard wound care alone. Adult patients with non-infected chronic wounds will be randomly assigned to one of two groups. One group will receive standard wound care only, while the other group will receive standard wound care plus subcutaneous dexpanthenol injections around the wound area.
Wound healing will be assessed by measuring changes in wound size and the degree of skin epithelialization over time using standardized and objective methods. Safety will be monitored by recording local reactions at the injection site and any other adverse events during the study.
The results of this study may provide preliminary clinical evidence on the effectiveness and safety of subcutaneous dexpanthenol as an additional treatment option for chronic wound management.
The 2 groups in the trial
- Intervention GroupTreatment being tested
Participants in this group will receive standard wound care plus perilesional subcutaneous dexpanthenol injections administered at predefined intervals according to a standardized protocol.
Treatment: Dexpanthenol and Standard Wound Care
- Control GroupExisting treatment, for comparison
Participants in this group will receive standardized wound care alone without subcutaneous dexpanthenol administration.
Treatment: Standard Wound Care
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluation of the Effect of Subcutaneous Dexpanthenol Administration on Wound Epithelialization: A Pilot Randomized Controlled Study
- Plain-language title
- Dexpanthenol injections under the skin for chronic wounds such as diabetic foot ulcersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 22 October 2026